News

The multinational study is investigating the safety and efficacy of Pari’s L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to Pari’s drug-device combination

Taspoglutide is similar to the naturally occurring human hormone GLP-1, which plays a key role in blood glucose metabolism through a range of mechanisms. They include: improvement of

Proteome Sciences will assist Parexel early phase experts in helping biopharmaceutical companies advance biomarker discovery and qualification within clinical trials. This expanded capability allows Parexel to offer its

The Alzheimer’s disease-specific antibodies were discovered using a platform being developed by OPKO that appears to be capable of identifying such biomarkers for any disease to which the

The company claims that NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent), with extended half-life and increased biologic activity. The pre-clinical results showed a positive pharmacokinetic profile which

Under the five-year agreement, CRL will be Neuren’s preferred partner for clinical development. CRL presently is supporting Neuren’s phase II clinical research program with NNZ-2566, providing site monitoring,

As a result, the Opposition Division of the European Patent Office has decided to revoke the Domantis patent in full. If this decision becomes final, all the claims

The investment program will be completed before the end of 2011. The centers will enforce sustainable development in the region and give a boost to Solvay’s presence in

Steve Turner, CEO of Protea, said: “We are pleased to have our technology recognised by the US patent office. Patents are the key assets of biotechnology, as they